Health
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
FOSTER CITY, Calif., April 14, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028.
About this update from Gilead Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1728,"height":576,"url":"https://media.zenfs.com/en/business-wire.com/89d387294b1b71b28a5721041df082e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4XQE7BMDIujTLUNhN_zuHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/89d387294b1b71b28a5721041df082e0","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/17wc81YJiXs2KYbqRXF_oA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA-/https://media.zenfs.com/en/business-wire.com/89d387294b1b71b28a5721041df082e0","width":1200,"height":400}},"lazy":false},{"type":"text","content":"– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years –","length":113,"tagName":"p","attribs":{}},{"type":"text","content":"FOSTER CITY, Calif., April 14, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028.","length":494,"tagName":"p"},{"type":"text","content":"Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead’s larger coordinated efforts to advance access to lenacapavir for HIV PrEP. These partners are experts in country delivery and distribution, with the reach and infrastructure to ensure these supplies reach those with the greatest need as quickly as possible. Lenacapavir is the first HIV prevention therapy to reach communities in sub-Saharan Africa in the same year it was approved in the United States, with initial shipments arriving at the end of 2025.","length":566,"tagName":"p"},{"type":"text","content":""Lenacapavir represents one of the most important breakthroughs ever seen in HIV prevention, and Gilead’s priority is to ensure broad access as quickly as possible," said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. "We expect large-scale generic roll...